Inventor · disambiguated record
Hans De Haard
Also filed as: DE HAARD HANS
24 granted patents·25 pending applications·42 citations·filing 2003–2025
94Inventor score
Files withABLYNX NV17STATEN BIOTECHNOLOGY B V10argenx BV7SHIRE HUMAN GENETIC THERAPIES5ARGENX IIP BV2
Top patents by PatentIndex Score
49 records- 0193US10844123B2Amino acid sequences that modulate the interaction between cells of the immune systemABLYNX NV·Filed 2018·Granted Nov 24, 2020·4 cites·25 claims
- 0293US10087251B2Amino acid sequences that modulate the interaction between cells of the immune systemABLYNX NV·Filed 2016·Granted Oct 2, 2018·9 cites·21 claims
- 0389US11161900B2Antibodies that specifically bind to human complement factor C2bARGENX BVBA·Filed 2019·Granted Nov 2, 2021·2 cites·12 claims
- 0489US10208115B2Amino acid sequences that modulate the interaction between cells of the immune systemABLYNX NV·Filed 2016·Granted Feb 19, 2019·5 cites·25 claims
- 0589US2024182575A1Amino acid sequences that modulate the interaction between cells of the immune systemABLYNX NV·Filed 2023·Application pending·0 cites
- 0687US9371381B2Single domain antibodies directed against tumor necrosis factor-alpha and uses thereforABLYNX NV·Filed 2014·Granted Jun 21, 2016·5 cites·16 claims
- 0785US12202900B2Compositions and methods for treating immune thrombocytopeniaargenx BV·Filed 2019·Granted Jan 21, 2025·4 cites·14 claims
- 0885US10538583B2Anti-APOC3 antibodies and compositions thereofSTATEN BIOTECHNOLOGY B V·Filed 2019·Granted Jan 21, 2020·3 cites·30 claims
- 0983US9320792B2Pulmonary administration of immunoglobulin single variable domains and constructs thereofABLYNX NV·Filed 2013·Granted Apr 26, 2016·4 cites·6 claims
- 1081US9725522B2Pulmonary administration of immunoglobulin single variable domains and constructs thereofABLYNX NV·Filed 2016·Granted Aug 8, 2017·2 cites·7 claims
- 1181US2024002484A1ANTIBODIES TO HUMAN COMPLEMENT FACTOR C2b AND METHODS OF USEargenx BV·Filed 2023·Application pending·0 cites
- 1280US11248042B2Polynucleotides encoding anti-ApoC3 antibodiesSTATEN BIOTECHNOLOGY B V·Filed 2019·Granted Feb 15, 2022·1 cites·15 claims
- 1379US11708403B2Antibodies to human complement factor C2B and methods of useargenx BV·Filed 2022·Granted Jul 25, 2023·0 cites·14 claims
- 1478US12435146B2Anti-Flt-1 antibodies for treating Duchenne muscular dystrophySHIRE HUMAN GENETIC THERAPIES·Filed 2023·Granted Oct 7, 2025·0 cites·9 claims
- 1578US11591386B2Antibodies to human complement C2Bargenx BV·Filed 2021·Granted Feb 28, 2023·0 cites·20 claims
- 1676US11858997B2Amino acid sequences that modulate the interaction between cells of the immune systemABLYNX NV·Filed 2020·Granted Jan 2, 2024·0 cites·21 claims
- 1776US11091539B2Anti-ApoC3 antibodies and methods of use thereofSTATEN BIOTECHNOLOGY B V·Filed 2019·Granted Aug 17, 2021·1 cites·4 claims
- 1873US10711065B2Anti-FLT-1 antibodies in treating bronchopulmonary dysplasiaSHIRE HUMAN GENETIC THERAPIES·Filed 2016·Granted Jul 14, 2020·1 cites·16 claims
- 1973US2025215090A1Compositions and methods for treating immune thrombocytopeniaargenx BV·Filed 2024·Application pending·0 cites
- 2071US11066473B2Galectin-10 antibodiesARGENX IIP BV·Filed 2019·Granted Jul 20, 2021·1 cites·24 claims
- 2171US2024026010A1Galectin-10 antibodiesargenx BV·Filed 2023·Application pending·0 cites
- 2271US2022251180A1Anti-apoc3 antibodiesSTATEN BIOTECHNOLOGY B V·Filed 2021·Application pending·0 cites
- 2370US11248041B2Anti-ApoC3 antibodiesSTATEN BIOTECHNOLOGY B V·Filed 2019·Granted Feb 15, 2022·0 cites·19 claims
- 2470US11230603B2Anti-GARP proteinLUDWIG INST FOR CANCER RES LTD·Filed 2020·Granted Jan 25, 2022·0 cites·15 claims
- 2566US10604579B2Antibody against a complex between human GARP and latent TGF-βLUDWIG INST FOR CANCER RES LTD·Filed 2018·Granted Mar 31, 2020·0 cites·5 claims
- 2666US2015266958A1Amino acid sequences that modulate the interaction between cells of the immune systemABLYNX NV·Filed 2014·Application pending·0 cites
- 2765US11242381B2Anti-ApoC3 antibodies and methods of use thereofSTATEN BIOTECHNOLOGY B V·Filed 2019·Granted Feb 8, 2022·0 cites·19 claims
- 2865US2022025026A1Anti-apoc3 antibodies and methods of use thereofSTATEN BIOTECHNOLOGY B V·Filed 2021·Application pending·0 cites
- 2965US2021206860A1Anti-flt-1 antibodies for treating duchenne muscular dystrophySHIRE HUMAN GENETIC THERAPIES·Filed 2020·Application pending·0 cites
- 3065US2022220193A1Anti-apoc3 antibodies and methods of use thereofSTATEN BIOTECHNOLOGY B V·Filed 2021·Application pending·0 cites
- 3164US2009022721A1Single domain antibodies directed against tumour necrosis factor-alpha and uses thereforABLYNX NV·Filed 2007·Application pending·0 cites
- 3264US2007237769A1Single domain antibodies directed against tumour necrosis factor-alpha and uses thereforABLYNX NV·Filed 2007·Application pending·0 cites
- 3364US2022025027A1Anti-apoc3 antibodies and methods of use thereofSTATEN BIOTECHNOLOGY B V·Filed 2021·Application pending·0 cites
- 3463US2007077249A1Single domain antibodies directed against tumour necrosis factor-alpha and uses thereforABLYNX NV·Filed 2006·Application pending·0 cites
- 3562US2017096481A1Single domain antibodies directed against tumor necrosis factor-alpha and uses thereforABLYNX NV·Filed 2016·Application pending·0 cites
- 3660US2012202977A1Single domain antibodies directed against tumor necrosis factor-alpha and uses thereforSILENCE KAREN·Filed 2012·Application pending·0 cites
- 3759US11713354B2Galectin-10 antibodiesARGENX IIP BV·Filed 2021·Granted Aug 1, 2023·0 cites·15 claims
- 3859US2011184150A1Single domain antibodies directed against tumor necrosis factor-alpha and uses thereforABLYNX NV·Filed 2011·Application pending·0 cites
- 3959US2021130475A1Anti-flt-1 antibodies in treating bronchopulmonary dysplasiaSHIRE HUMAN GENETIC THERAPIES·Filed 2020·Application pending·0 cites
- 4058US2011027281A1Single domain antibodies directed against tumor necrosis factor-alpha and uses thereforABLYNX NV·Filed 2010·Application pending·0 cites
- 4157US10787515B2Anti-Flt-1 antibodies for treating duchenne muscular dystrophySHIRE HUMAN GENETIC THERAPIES·Filed 2016·Granted Sep 29, 2020·0 cites·11 claims
- 4257US2006034845A1Single domain antibodies directed against tumor necrosis factor alpha and uses thereforSILENCE KAREN·Filed 2003·Application pending·0 cites
- 4357US2010136018A1Anti-FC-receptor single domain antibodies (nanobodies-tm) and therapeutic useABLYNX NV·Filed 2007·Application pending·0 cites
- 4455US2021347865A1Antibodies specific for human and cynomolgus apoc3 and methods of use thereofSTATEN BIOTECHNOLOGY B V·Filed 2021·Application pending·0 cites
- 4555US2016251438A1Anti-garp protein and uses thereofARGEN-X N V·Filed 2016·Application pending·0 cites
- 4655US2025230252A1Treatment for acute myeloid leukemia with anti-cd70 antibodiesargenx BV·Filed 2025·Application pending·0 cites
- 4754US2019106498A1Treatment for acute myeloid leukemiaDE HAARD HANS·Filed 2018·Application pending·0 cites
- 4845US2009252681A1Nanobodies and Polypeptides Against EGFR and IGF-IRABLYNX NV·Filed 2006·Application pending·0 cites
- 4931US11597763B2Anti-Kv1.3 antibodies, and methods of production and use thereofTETRAGENETICS INC·Filed 2017·Granted Mar 7, 2023·0 cites·2 claims
Join the waitlist — get patent alerts
Get an alert when Hans De Haard files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →